Noguchi: Mahama commissions DNA, vaccine laboratories to boost Ghana’s health security
President John Dramani Mahama has commissioned a National Human Identification Laboratory and a Vaccine Research Facility at the Noguchi Memorial Institute for Medical Research, pledging to strengthen Ghana’s health security and scientific capacity.
The two facilities are expected to boost the country’s ability to conduct DNA analysis locally, support forensic investigations and advance research and development of vaccines.
Speaking at the commissioning ceremony on Wednesday, November 18, President Mahama said the investment marked an important step towards building a more self-reliant healthcare system capable of responding to national emergencies and emerging disease threats.
“By commissioning these facilities today, we affirm our collective determination to build a Ghana that can safeguard its health security, advance scientific innovation, and chart its own course towards prosperity,” he said.
The Human Identification Laboratory, popularly known as the DNA Laboratory, is expected to help identify human remains, support police investigations and resolve paternity and other identity-related disputes.
President Mahama said the need for the facility became urgent following the August 6, 2025 helicopter crash, which claimed eight lives and required samples from the accident site to be sent to South Africa for DNA analysis.
He described Ghana’s inability to conduct the tests locally at the time as a national embarrassment.
“It was a day of shame for Ghana that we couldn’t carry out our own DNA analysis in-country. That will be a thing of the past. I am proud now that we have a world-class facility that will strengthen our forensic and public health systems,” he stated.
The second facility comprises mRNA and protein laboratories designed to support vaccine research, development and collaboration among Ghanaian scientists and their international counterparts.
President Mahama said the investment would help reduce Ghana’s dependence on foreign vaccine supplies, particularly during public health emergencies.
He recalled how African countries struggled to access vaccines during the COVID-19 pandemic, saying disruptions to global supply chains exposed the disadvantages of relying on external manufacturers.
The President also urged Ghanaians to support clinical trials, describing public participation as essential to developing vaccines locally.
“And so if we are developing our own internal capacity to develop vaccines, we must accept to take part in the clinical trials. Nobody will do the clinical trials for us to develop vaccines in our country. And so that is my message to you,” he said.
He further disclosed that Ghana had allocated $1 billion to the pharmaceutical sector under the Seventh Pillar of the New Economy programme to support pharmaceutical and biomanufacturing hubs in the Eastern, Central and Volta regions.
President Mahama said the government would continue investing in local scientific expertise and partnerships to strengthen the country’s pharmaceutical industry and improve health outcomes.
He expressed confidence that the two facilities would position Ghana to take greater responsibility for the health and wellbeing of its people while contributing to Africa’s scientific and public health development.
Comments (0)
No comments yet. Be the first to share your opinion!